The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

This study aims to evaluate the efficacy and safety of TQB2102 for injection in HER2 negative recurrent/metastatic breast cancer.

Trial Details

NCT ID
NCT06452706
Phase
PHASE2
Sponsor
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Status
RECRUITING
Cancer Type
HER2 Negative Breast Cancer
Interventions
  • TQB2102 for injection
Locations (sample)
  • Bozhou, Anhui, China|33.87722,115.77028
  • Chuzhou, Anhui, China|32.32194,118.29778
  • Hefei, Anhui, China|31.86389,117.28083
  • Ma’anshan, Anhui, China|31.68579,118.51008
  • Wuhu, Anhui, China|31.35259,118.42947

Key Eligibility Criteria

  • The participants voluntarily participate in the study and sign an informed consent form.
  • Age: 18-75 years old; Eastern Cooperative Oncology Group (ECOG) score: ≤1 point; Expected survival period exceeds 3 months.
  • Breast cancer patients diagnosed as HER2 negative by pathology, with evidence of local recurrence or distant metastasis are not suitable for surger…
  • Sufficient tumor tissue samples must be available for HER2 evaluation by pathologists at the main research center.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Negative Breast Cancer Trials on Trialify →